|
KLF3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.03190028638767E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.88589999955613E-07 |
| Normal-vs-Stage2 |
4.44219999999884E-05 |
| Normal-vs-Stage3 |
6.09899908354805E-11 |
| Normal-vs-Stage4 |
5.49570389196674E-11 |
| Stage1-vs-Stage2 |
8.681800E-01 |
| Stage1-vs-Stage3 |
1.247650E-02 |
| Stage1-vs-Stage4 |
5.640800E-04 |
| Stage2-vs-Stage3 |
1.203950E-01 |
| Stage2-vs-Stage4 |
2.048100E-02 |
| Stage3-vs-Stage4 |
2.785400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.6874003850329E-10 |
| Normal-vs-AfricanAmerican |
8.155500E-04 |
| Normal-vs-Asian |
3.94910000000026E-05 |
| Caucasian-vs-AfricanAmerican |
7.316400E-01 |
| Caucasian-vs-Asian |
5.921600E-01 |
| AfricanAmerican-vs-Asian |
9.615000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.7983000078512E-09 |
| Normal-vs-Female |
2.51340004364664E-09 |
| Male-vs-Female |
6.131000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.18340000002204E-06 |
| Normal-vs-Age(41-60Yrs) |
2.32789998388938E-09 |
| Normal-vs-Age(61-80Yrs) |
3.88660215122627E-11 |
| Normal-vs-Age(81-100Yrs) |
7.939400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.667990E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.158330E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.709200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.915650E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.770800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.290800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.788800E-04 |
| Classical-VS-Follicular |
5.967200E-01 |
| Classical-VS-Other |
3.725400E-01 |
| Classical-VS-Normal |
3.19120000424888E-08 |
| Tall-VS-Follicular |
1.644300E-02 |
| Tall-VS-Other |
6.053800E-01 |
| Tall-VS-Normal |
2.76940026466832E-10 |
| Follicular-VS-Other |
5.305600E-01 |
| Follicular-VS-Normal |
2.82990000000094E-06 |
| Other-VS-Normal |
5.315500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.75359995600178E-09 |
| Normal-vs-N1 |
2.66260002934615E-09 |
| N0-vs-N1 |
7.380100E-02 |
|
|
